TroVax
TroVax
TroVax (pronounced: troh-vaks) is a cancer vaccine developed by Oxford BioMedica, a UK-based biopharmaceutical company. It is designed to stimulate the immune system to destroy cancer cells.
Etymology
The name "TroVax" is a combination of the words "tumor" and "vaccine", reflecting its purpose as a cancer vaccine.
Description
TroVax is a therapeutic vaccine that targets the 5T4 antigen, a protein present on the surface of many different types of cancer cells. The vaccine is designed to stimulate the body's immune system to recognize and destroy cancer cells expressing the 5T4 antigen.
Clinical Trials
TroVax has been evaluated in several clinical trials for various types of cancer, including renal cell carcinoma, prostate cancer, and colorectal cancer. The results of these trials have shown promise, but further research is needed to fully understand the vaccine's potential benefits and risks.
Related Terms
- Cancer vaccine
- 5T4 antigen
- Oxford BioMedica
- Clinical trial
- Renal cell carcinoma
- Prostate cancer
- Colorectal cancer
External links
- Medical encyclopedia article on TroVax
- Wikipedia's article - TroVax
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski